Leerink Partnrs Has Negative Estimate for Pfizer Q3 Earnings

Pfizer Inc. (NYSE:PFE) – Stock analysts at Leerink Partnrs dropped their Q3 2025 earnings per share estimates for Pfizer in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings per share of $1.10 for the quarter, down from their previous forecast of $1.11. The consensus estimate for Pfizer’s current full-year earnings is $2.96 per share. Leerink Partnrs also issued estimates for Pfizer’s FY2029 earnings at $2.36 EPS.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue was up 24.7% on a year-over-year basis. During the same period last year, the business earned $0.10 earnings per share.

PFE has been the subject of a number of other reports. Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Bank of America reiterated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Sanford C. Bernstein assumed coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Down 2.3 %

Shares of NYSE PFE opened at $25.83 on Friday. The business has a fifty day moving average of $26.29 and a two-hundred day moving average of $27.78. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer has a 52-week low of $24.48 and a 52-week high of $31.54. The stock has a market cap of $146.35 billion, a PE ratio of 34.90, a PEG ratio of 0.66 and a beta of 0.64.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.66%. Pfizer’s payout ratio is presently 232.44%.

Institutional Investors Weigh In On Pfizer

Several institutional investors have recently bought and sold shares of PFE. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the 4th quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $28,000. Gladius Capital Management LP raised its stake in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares in the last quarter. Noble Wealth Management PBC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $31,000. Finally, Sierra Ocean LLC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.